SCHEMBL323321

SCHEMBL323321

COc1cccc(COC(=O)N2C=Cc3ccccc3C2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
MMP12 P39900 2/20 0.43
THRB P10828 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
NAMPT P43490 3/20 0.40
IDO1 P14902 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324667 0.87 P2RX4 (0.48) NPC1RAB9AMMP1MMP9ALDH1A1
SCHEMBL324589 0.86 GRIN2B (0.41) NPC1RAB9AMMP2MMP9MMP12
SCHEMBL324299 0.84 P2RX4 (0.52) NPC1RAB9AALDH1A1SIGMAR1P2RX4
SCHEMBL325206 0.84 HCAR2 (0.43) NPC1RAB9AMMP1MMP2MMP9
SCHEMBL323355 0.84 HCAR2 (0.43) RAB9AMMP1MMP2MMP9MMP12
SCHEMBL325470 0.83 KDM4E (0.44) KDM4EALDH1A1MAPTNAMPT
SCHEMBL324049 0.81 FFAR1 (0.40) MAOAMAOBMRGPRX4NAMPTP2RX4
SCHEMBL323429 0.81 PRKCA (0.46) MMP1MMP12THRBMAOBMRGPRX4
SCHEMBL324346 0.81 P2RX4 (0.47) NPC1RAB9AMMP1MMP2MMP9
SCHEMBL323741 0.81 GABRA1 (0.36) ALDH1A1MAPTMRGPRX4NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 NPC1 2089/4885RAB9A 1846/4885MMP1 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.